RemeGen reports 48% revenue jump, cuts losses 42%

RemeGen Co., Ltd. reported revenue of RMB1,092.0 million for the six months ended June 30, 2025, a 47.6% increase from RMB739.7 million in the prior year. Growth was driven by robust sales of telitacicept and disitamab vedotin.

The company's loss decreased by RMB330.9 million, or 42.4%, to RMB449.6 million. Research and development expenses fell 19.7% to RMB647.2 million due to reduced R&D personnel and optimized projects.